The Treatment of Advanced Melanoma: Therapeutic Update

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jun 24

PMID 35742834

Authors

Alessia Villani

Luca Potestio

Gabriella Fabbrocini

Giancarlo Troncone

Umberto Malapelle

Massimiliano Scalvenzi

Affiliations

Soon will be listed here.

Abstract

Cutaneous melanoma is the main cause of death for skin cancer. The majority of patients with a diagnosis of melanoma have localized disease, which can be successfully treated with surgical treatment. However, the surgical approach is not curative for advanced melanoma (AM). Indeed, the management of AM is still challenging, since melanoma is the solid tumor with the highest number of mutations and cancer cells have the capacity to evade the immune system. In the past, the treatment of AM relied on chemotherapeutic agents, without showing efficacy data. Recent knowledge on melanoma pathogenesis as well as the introduction of immunotherapies, targeted therapies vaccines, small molecules, and combination therapies has revolutionized AM management, showing promising results in terms of effectiveness and safety. The aim of this review is to assess and to discuss the role of emerging therapies for AM management in order to obtain a complete overview of the currently available treatment options and future perspectives.

Citing Articles

Exploring the Therapeutic Potential of Vesicular Nanocarrier Systems for Elimination of Skin Cancer.

Kumar L, Rana R, Komal K, Aggarwal V, Kumar S, Choudhary N Curr Med Chem. 2025; 32(2):258-285.

PMID: 39962707 DOI: 10.2174/0109298673297695240328074724.

Carboxylesterase 1-mediated endocannabinoid metabolism in skin: role in melanoma progression in BRaf/Pten mice.

Morozova V, Pellegata D, Charles R, Gertsch J Cancer Metab. 2025; 13(1):8.

PMID: 39934865 PMC: 11817774. DOI: 10.1186/s40170-025-00378-2.

Fasting as an Adjuvant Therapy for Cancer: Mechanism of Action and Clinical Practice.

Xie Y, Ye H, Liu Z, Liang Z, Zhu J, Zhang R Biomolecules. 2024; 14(11).

PMID: 39595613 PMC: 11591922. DOI: 10.3390/biom14111437.

Swimming upregulates APOL3 through regulating macrophage polarization to inhibit glycolysis and the development of melanoma.

Lyu Z, Mahenderan A, Radhakrishnan A, Chin Y, Yin C 3 Biotech. 2024; 14(12):307.

PMID: 39583207 PMC: 11582285. DOI: 10.1007/s13205-024-04150-z.

Exploring mechanisms of skin aging: insights for clinical treatment.

Zhang M, Lin Y, Han Z, Huang X, Zhou S, Wang S Front Immunol. 2024; 15:1421858.

PMID: 39582871 PMC: 11581952. DOI: 10.3389/fimmu.2024.1421858.

References

Giblin A, Thomas J . Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2006; 60(1):32-40. DOI: 10.1016/j.bjps.2006.05.008. View

Robert C, Ribas A, Schachter J, Arance A, Grob J, Mortier L . Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(9):1239-1251. DOI: 10.1016/S1470-2045(19)30388-2. View

Jenkins R, Fisher D . Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2020; 141(1):23-31. PMC: 7541692. DOI: 10.1016/j.jid.2020.03.943. View

Weber J, Mandala M, Del Vecchio M, Gogas H, Arance A, Cowey C . Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017; 377(19):1824-1835. DOI: 10.1056/NEJMoa1709030. View

Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S . Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19):1789-1801. DOI: 10.1056/NEJMoa1802357. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View

Villani A, Scalvenzi M, Fabbrocini G, Ocampo-Candiani J, Ocampo-Garza S . Looking into a Better Future: Novel Therapies for Metastatic Melanoma. Dermatol Ther (Heidelb). 2021; 11(3):751-767. PMC: 8163929. DOI: 10.1007/s13555-021-00525-9. View

Hartman R, Lin J . Cutaneous Melanoma-A Review in Detection, Staging, and Management. Hematol Oncol Clin North Am. 2018; 33(1):25-38. DOI: 10.1016/j.hoc.2018.09.005. View

Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C . OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther. 2019; 12:7347-7353. PMC: 6735535. DOI: 10.2147/OTT.S214211. View

10.

Diab A, Tykodi S, Daniels G, Maio M, Curti B, Lewis K . Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol. 2021; 39(26):2914-2925. PMC: 8425826. DOI: 10.1200/JCO.21.00675. View

11.

Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S . Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22(5):643-654. DOI: 10.1016/S1470-2045(21)00065-6. View

12.

Corrie P, Marshall A, Dunn J, Middleton M, Nathan P, Gore M . Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014; 15(6):620-30. DOI: 10.1016/S1470-2045(14)70110-X. View

13.

Senzer N, Kaufman H, Amatruda T, Nemunaitis M, Reid T, Daniels G . Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009; 27(34):5763-71. DOI: 10.1200/JCO.2009.24.3675. View

14.

Spitler L, Boasberg P, ODay S, Hamid O, Cruickshank S, Mesko S . Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. Am J Clin Oncol. 2015; 38(1):61-7. DOI: 10.1097/COC.0b013e318287bbae. View

15.

Long G, Atkinson V, Cebon J, Jameson M, Fitzharris B, McNeil C . Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017; 18(9):1202-1210. DOI: 10.1016/S1470-2045(17)30428-X. View

16.

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View

17.

Schachter J, Ribas A, Long G, Arance A, Grob J, Mortier L . Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017; 390(10105):1853-1862. DOI: 10.1016/S0140-6736(17)31601-X. View

18.

Chanal J, Kramkimel N, Ratour C, Aractingi S, Guegan S, Avril M . Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age. Dermatology. 2019; 235(3):219-224. DOI: 10.1159/000492467. View

19.

Khushalani N, Diab A, Ascierto P, Larkin J, Sandhu S, Sznol M . Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncol. 2020; 16(28):2165-2175. DOI: 10.2217/fon-2020-0351. View

20.

Lee J, Kim H, Ha S . Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Netw. 2022; 22(1):e2. PMC: 8901707. DOI: 10.4110/in.2022.22.e2. View